orbed by all the cells in the body. Due to their increased rate of
metabolic activity, cancerous cells in the breast absorb a greater amount of
the tracing agent than the normal surrounding tissue and generally appear as
"hot spots" on the BSGI image.
"Both tests are good in detecting breast cancer with similar sensitivity
for cancer. Along with benefits of cost-effectiveness and comfort, BSGI can be
more helpful in excluding inconclusive MRI results. The use of BSGI in this
group can result in fewer unnecessary MRI guided biopsies. The reassurance
from a truly negative test, indicating that she does not have breast cancer,
is priceless information for the patient," said Dr. Lanzkowsky. The work will
continue at the Nevada Imaging Centers in Las Vegas, where a new state of the
art breast center in association with a high risk clinic will incorporate the
Breast specific gamma imaging technology with other state of the art
technologies in the assessment of women with both moderate as well as high
risk for the development of breast cancer.
About Dilon Technologies
Dilon Technologies Inc. is bringing innovative new medical imaging
products to market. Dilon's cornerstone product, the Dilon 6800, is a
high-resolution, small field-of-view gamma camera, optimized to perform BSGI,
a molecular breast imaging procedure which images the metabolic activity of
breast lesions through radiotracer uptake. Many leading medical centers around
the country are now offering BSGI to their patients, including: Cornell
University Medical Center, New York; George Washington University Medical
Center, Washington, D.C.; and The Rose, Houston. For more information on
Dilon Technologies please visit http://www.dilon.com.
'/>"/>SOURCE Dilon Technologies Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
A new molecular zip code, and a new drug target for Huntingtons disease2.
New knock-out gene model provides molecular clues to breast cancer3.
Molecular probe paints cancer cells in living animals, Stanford researchers find4.
Story ideas from molecular & cellular proteomics5.
SNM seeks novel approaches to molecular imaging to showcase at annual meeting6.
SNM seeks novel approaches to molecular imaging to showcase at annual meeting7.
Molecular fingerprint of breast-cancer drug resistance can predict response to treatment8.
Molecular profiling can accurately predict survival in colon cancer patients9.
Xceed Molecular Names Fran Tuttle to Its Board of Trustees10.
Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative11.
Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85